

ETHICON

Biosurgery

Xiao-yu Song, M.D., Ph.D.



Xiao-yu Song is Vice President of Research & Development for Ethicon Biosurgery. Xiao-yu leads a global organization of researchers and scientists/engineers dedicated to developing new innovations to meet specific unmet medical needs. She has overall responsibility for new product development and life cycle management of marketed products across all Ethicon Biosurgery platforms: human and porcine plasma derived Biologics, Devices, Biologics/Device combination products, Polymer, Synthetics, and Biopatch and additional responsibility for Global Surgery Group Preclinical Center of Excellence.

Prior to joining Ethicon in 2006, Xiao-yu worked for Centocor, Inc., part of the Johnson & Johnson Family of Pharmaceutical Companies, with experiences spanning from discovery research to monoclonal antibody compound development as well as identification of disease biomarkers, mechanism of action based, and response to therapy biomarkers to increase the possibility of clinical success.

Xiao-yu completed her postdoctoral training in autoimmunity and immunology at NIH, Bethesda, MD. She has several issued patents and over 35 articles published in peer-reviewed journals and has been invited to speak at national and international scientific conferences. Xiao-yu earned her Ph.D. in Biology from University of North Carolina at Chapel Hill, M.S. in Biochemistry, and her M.D. at China Medical University.